INS and Hyperglycemia: Additionally, Glucagon-like peptide-1 (GLP-1) exerts glucose-dependent effects by augmenting insulin secretion, inhibiting glucagon release, and supporting β-cell regeneration, thereby ameliorating hyperglycemia in T2DM patients [9].